GlaxoSmithKline (GSK) has confirmed that the European Commission has granted marketing authorisation for its H1N1 influenza vaccine Pandemrix.

GSK Biologicals president Jean Stéphenne said that following the Commission’s approval, the company expects to begin shipments of Pandemrix to European governments from next week.

The approval was based on the results of clinical trials that demonstrated the vaccine can provide a strong immune response, exceeding the required immunogenicity criteria, after one dose.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData